Drugs and patents in ATC class N06AF - Monoamine oxidase inhibitors, non-selective

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
MARPLAN	isocarboxazid
NARDIL	phenelzine sulfate
PHENELZINE SULFATE	phenelzine sulfate
PARNATE	tranylcypromine sulfate
TRANYLCYPROMINE SULFATE	tranylcypromine sulfate
>Tradename	>Generic Name

Last updated: February 19, 2026

Overview

The patent landscape for non-selective monoamine oxidase inhibitors (MAOIs) is characterized by a decline in novel patent filings as the class matures and a concentration of intellectual property around specific compounds and their applications. While early patents have long expired, recent activity focuses on process patents, new formulations, and combination therapies. The market faces challenges from newer antidepressant classes with improved side effect profiles, but a niche exists for MAOIs in treatment-resistant depression and specific neurological conditions.

Therapeutic Rationale and Mechanism of Action

Non-selective MAOIs inhibit both monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B). These enzymes are responsible for the breakdown of neurotransmitters including serotonin, norepinephrine, dopamine, and tyramine. By inhibiting MAO, these drugs increase the synaptic availability of these neurotransmitters, exerting their therapeutic effects. MAO-A primarily metabolizes serotonin and norepinephrine, while MAO-B metabolizes dopamine and phenylethylamine. Non-selective inhibitors therefore impact a broader range of neurotransmitter systems. This broad action contributes to their efficacy but also their potential for drug-drug and drug-food interactions.

Key Patent Trends for Non-Selective MAOIs

The primary period of patent filings for the foundational non-selective MAOI molecules has passed, with most original composition of matter patents expiring decades ago. Current patent activity revolves around:

Process Patents: Improvements in the synthesis and manufacturing of existing MAOI compounds. These patents aim to optimize yield, purity, and cost-effectiveness of production.
Formulation Patents: Development of new dosage forms, such as extended-release formulations, transdermal patches, or orally disintegrating tablets. These innovations seek to improve patient compliance, reduce side effects, and enhance therapeutic outcomes.
Combination Therapies: Patents covering the co-administration of MAOIs with other active pharmaceutical ingredients (APIs) to achieve synergistic effects or mitigate adverse reactions.
New Indications: Exploration and patenting of MAOIs for conditions beyond their traditional use in depression, including Parkinson's disease and other neurological disorders where monoamine dysregulation is implicated.

Major Non-Selective MAOI Compounds and Their Patent Status

Several compounds fall under the non-selective MAOI classification. The patent status of the most prominent ones highlights the evolving intellectual property landscape.

Compound Name	ATC Code	Original Patent Expiry (Approximate)	Key Recent Patent Activity Area
Phenelzine	N06AF03	Mid-1970s	Formulation, manufacturing process
Tranylcypromine	N06AF02	Mid-1970s	Formulation, manufacturing process
Isocarboxazid	N06AF01	Early 1980s	Formulation, manufacturing process

Note: Original patent expiry dates are estimates based on typical patent terms of the era and may vary based on specific filings, extensions, and geographic regions.

Phenelzine

Phenelzine, a hydrazine derivative, was among the earliest non-selective MAOIs. Its composition of matter patents have long expired. Current patent filings associated with phenelzine primarily address:

Manufacturing Process Improvements: Patents have been granted for novel synthetic routes that offer higher purity or reduced byproducts. For example, patents might detail specific reaction conditions, catalysts, or purification techniques.
Formulation Development: The development of extended-release phenelzine formulations aims to provide smoother plasma concentration profiles, potentially reducing peak-related side effects and improving dosing convenience. These patents protect the specific excipients and manufacturing methods used to achieve controlled release.

Tranylcypromine

Tranylcypromine, a cyclopropylamine derivative, also has expired composition of matter patents. Recent patenting activity for tranylcypromine includes:

Transdermal Delivery Systems: Patents have explored the use of transdermal patches for tranylcypromine. This approach aims to bypass first-pass metabolism and provide a steady release of the drug, potentially improving tolerability and adherence.
Novel Salt Forms and Polymorphs: While less common, patents may arise for specific crystalline forms or salt preparations of tranylcypromine that exhibit improved stability, solubility, or bioavailability.
Combination Products: Research has investigated combining tranylcypromine with other APIs, for instance, in the treatment of resistant depression. Patents in this area would cover the specific combination and its therapeutic use.

Isocarboxazid

Isocarboxazid, another hydrazine derivative, has seen its foundational patents expire. Patent activity related to isocarboxazid focuses on:

Enhanced Bioavailability Formulations: Patents may protect new oral dosage forms designed to improve the absorption of isocarboxazid, thereby increasing its efficacy or allowing for lower doses.
Stabilized Formulations: Addressing potential stability issues of the drug substance or formulated product through novel excipients or manufacturing processes is another area for patent protection.

Market Dynamics and Competitive Landscape

The market for non-selective MAOIs has contracted significantly due to several factors:

Emergence of Second and Third-Generation Antidepressants: Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) offer comparable efficacy for many patients with a more favorable side effect profile and fewer dietary restrictions. These newer classes now dominate the antidepressant market.
Safety Concerns: The significant risk of hypertensive crisis due to dietary tyramine (the "cheese effect") and interactions with sympathomimetic drugs remains a major barrier to widespread MAOI use. Strict dietary adherence and careful medication management are required, limiting their appeal.
Dosing Complexity: The need for slow titration, specific dietary regimens, and close patient monitoring adds to the complexity of MAOI treatment.

Despite these challenges, non-selective MAOIs retain a critical role in specific patient populations:

Treatment-Resistant Depression (TRD): For individuals who have failed multiple trials of other antidepressant classes, non-selective MAOIs, particularly tranylcypromine and phenelzine, can be highly effective. This niche market supports the continued demand for these agents.
Atypical Depression: Certain subtypes of depression, characterized by mood reactivity, hypersomnia, and leaden paralysis, may respond better to MAOIs than to other antidepressants.
Parkinson's Disease: While selective MAO-B inhibitors are primarily used for Parkinson's, non-selective MAOIs can also be employed, particularly in early stages or in combination therapies.
Other Neurological and Psychiatric Disorders: Research continues into the potential use of MAOIs for conditions like bulimia nervosa, social anxiety disorder, and narcolepsy, although these are often off-label or investigational uses.

Key Market Players and IP Holders

The manufacturers of generic non-selective MAOIs remain the primary entities involved in the current patent landscape. These include companies focused on generic drug production and those specializing in niche or older psychiatric medications.

Generic Manufacturers: Companies like Teva Pharmaceuticals, Mylan (now Viatris), and Accord Healthcare hold manufacturing and distribution rights for generic versions of phenelzine, tranylcypromine, and isocarboxazid. Their patent activity would be concentrated on process and formulation improvements to maintain competitive advantage in the generic space.
Specialty Pharmaceutical Companies: A limited number of companies focus on developing and marketing psychiatric medications, including older classes. These companies may actively seek patents on novel formulations or delivery systems for MAOIs to create differentiated products within the TRD market.

Regulatory Considerations

The Food and Drug Administration (FDA) and other global regulatory bodies impose strict requirements on MAOIs due to their safety profile.

Boxed Warnings: All non-selective MAOIs carry a boxed warning regarding the risk of serious, potentially fatal drug-food (tyramine) and drug-drug interactions.
Risk Evaluation and Mitigation Strategies (REMS): While not always mandated for all older drugs, REMS programs or similar strict prescribing guidelines are often associated with MAOIs to ensure prescribers and patients are fully aware of the risks and required precautions. This includes providing educational materials and requiring physician certification.
Post-Market Surveillance: Regulatory agencies closely monitor adverse event reports for MAOIs to identify any emerging safety signals.

Future Outlook

The future of non-selective MAOIs is tied to their established efficacy in treatment-resistant populations and ongoing research into specialized applications.

Continued Niche Demand: The market for TRD is expected to sustain demand for effective, albeit riskier, treatments.
Formulation Innovation: Patents for improved delivery systems (e.g., transdermal, extended-release) could enhance tolerability and compliance, potentially expanding their utility.
Investigational Uses: Further research into MAOIs for conditions beyond depression and Parkinson's could uncover new therapeutic avenues, leading to future patent filings for specific indications.
Generic Competition: The dominance of generic versions means that profitability for manufacturers will largely depend on efficient production and cost management, with patent protection focused on manufacturing processes and subtle formulation improvements.
Limited New Molecular Entities: The high bar for safety and efficacy, coupled with the availability of newer antidepressant classes, makes the development of novel non-selective MAOI compounds unlikely.

Key Takeaways

The patent landscape for non-selective MAOIs is dominated by process and formulation patents, as foundational composition of matter patents have expired.
Market demand is primarily driven by treatment-resistant depression and specific neurological conditions, despite competition from newer antidepressant classes.
Safety concerns related to drug-food and drug-drug interactions remain the principal limiting factor for wider MAOI use.
Key players are primarily generic manufacturers and specialty pharmaceutical companies focusing on niche markets.
Future patent activity is likely to center on innovative delivery systems and potential new indications rather than novel molecular entities.

Frequently Asked Questions

What is the primary reason for the limited number of new patents on non-selective MAOI compounds? The primary reason is that the core molecules were developed decades ago, and their original composition of matter patents have long expired. The therapeutic landscape has also shifted towards newer drug classes with better safety profiles, making investment in novel MAOI molecule development less attractive.
How do recent patents on formulations impact the market for non-selective MAOIs? Patents on new formulations, such as extended-release versions or transdermal patches, aim to improve patient compliance and reduce side effects. Successful implementation can differentiate these products in a crowded generic market and potentially expand their therapeutic utility by making them more manageable for patients.
Are there any significant new therapeutic indications being pursued for non-selective MAOIs that could lead to future patent protection? While research is ongoing, the most established new area of interest is in specific subtypes of treatment-resistant depression. Patents may be sought for MAOIs when used in combination therapies or for specific patient profiles within this broader category. Exploration into other neurological disorders is also a possibility.
Who are the main entities holding intellectual property related to non-selective MAOIs today? The main entities are generic drug manufacturers who hold patents on optimized manufacturing processes and specific formulation techniques to maintain a competitive edge in the generic market. Specialty pharmaceutical companies that focus on niche psychiatric markets may also hold patents on proprietary formulations or delivery systems.
What is the most significant challenge non-selective MAOIs face from a regulatory and market perspective? The most significant challenge is the inherent risk of serious, potentially fatal drug-food (specifically tyramine-rich foods) and drug-drug interactions. This necessitates strict patient and physician education, dietary restrictions, and careful monitoring, limiting their widespread adoption compared to newer antidepressants with more favorable safety profiles.

Citations

[1] Schacht, U., & Bebbington, A. (1990). Monoamine oxidase inhibitors. Journal of Clinical Psychiatry, 51(Suppl.), 10-15. [2] Goodwin, G. M. (2006). Depression and Parkinson's disease. The Lancet, 367(9508), 414-414. [3] National Institute of Mental Health. (n.d.). Depression. Retrieved from [NIMH Website] [4] United States Food and Drug Administration. (n.d.). Drug Safety Communications. Retrieved from [FDA Website]

Drugs in ATC Class N06AF

Drugs in ATC Class: N06AF - Monoamine oxidase inhibitors, non-selective

Monoamine Oxidase Inhibitors (Non-Selective): Patent Landscape and Market Dynamics